A distinct variant of mixed dysarthria reflects parkinsonism and dystonia due to ephedrone abuse

Journal of Neural Transmission

Volumn 121, Issue 6, 2014, Pages 655-664

  Rusz, Jan ^a,b   Megrelishvili, Marika ^c,d   Bonnet, Cecilia ^b   Okujava, Michael ^c,e   Brožová, Hana ^b   Khatiashvili, Irine ^c,d   Sekhniashvili, Madona ^d   Janelidze, Marina ^d   Tolosa, Eduardo ^f   Růžička, Evžen ^b  

^a CZECH TECHNICAL UNIVERSITY IN PRAGUE   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c ILIA STATE UNIVERSITY   (Georgia)

^d National Oncology Centre Khechinashvili University Hospital   (Georgia)

^e Research Institute of Clinical Medicine   (Georgia)

^f UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Acoustic analysis; Dystonia; Ephedrone; Manganese; Methcathinone; Speech disorder

Indexed keywords

METHCATHINONE; ANTIPARKINSON AGENT; MONOMETHYLPROPION; PROPIOPHENONE DERIVATIVE;

ACOUSTIC ANALYSIS; ADULT; ARTICLE; BRADYKINESIA; CAUCASIAN; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ABUSE; DYSARTHRIA; DYSTONIA; HUMAN; LOUDNESS; MALE; MIXED DYSARTHRIA; NEUROIMAGING; NNIPPS PARKINSON PLUS SCALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSONISM; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RATING SCALE; SPEECH ANALYSIS; UNITED STATES; ACOUSTICS; ADDICTION; ANALYSIS OF VARIANCE; COMPLICATION; MENTAL HEALTH; MIDDLE AGED; PARKINSONIAN DISORDERS; SEVERITY OF ILLNESS INDEX; STATISTICS;

ACOUSTICS; ADULT; ANALYSIS OF VARIANCE; ANTIPARKINSON AGENTS; DYSARTHRIA; DYSTONIA; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MENTAL STATUS SCHEDULE; MIDDLE AGED; PARKINSONIAN DISORDERS; PROPIOPHENONES; SEVERITY OF ILLNESS INDEX; STATISTICS AS TOPIC; SUBSTANCE-RELATED DISORDERS;

EID: 84901850784     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-014-1158-6     Document Type: Article

References (33)

1. Albin RL, Young AB, Penney JB (1989) The functional anatomy of basal ganglia disorders. Trends Neurosci 12:366-375
2. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J (1961) An inventory for measuring depression. Arch Gen Psychiatry 4:561-571
3. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F (1973) Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci 20:415-455
4. Boersma P, Weenink D (2001) PRAAT, a system for doing phonetics by computer. Glot Int 5:341-345
5. Butterworth RF, Spahr L, Fontaine S, Layratgues GP (1995) Manganese toxicity, dopaminergic dysfunction and hepatic encephalopathy. Metab Brain Dis 10:259-267
6. Cersosimo MG, Koller WC (2006) The diagnosis of manganese-induced parkinsonism. Neurotoxicology 27:340-346
7. Darley FL, Aronson AE, Brown JR (1969) Differential diagnostic patterns of dysarthria. J Speech Hear Res 12:246-269
8. Dubois B, Slachevsky A, Litvan I, Pillon B (2000) The FAB: a frontal battery at bedside. Neurology 55:1621-1626
9. Duffy JR (2005) Motor speech disorders: substrates, differential diagnosis and management, 2nd edn. Mosby, New York
10. Espay AJ, Beaton DE, Morgante F, Gunraj CA, Lang AE, Chen R (2009) Impairment of speed and amplitude of movement in Parkinson's disease: a pilot study. Mov Disord 24:1001-1008
11. Fisher E, Goberman AM (2010) Voice onset time in Parkinson's disease. J Commun Disord 43:21-34
12. Folstein MF, Folstein SE, McHugh PR (1975) "Mini-mental state": a practical method for grading the cognitive state of patients for the clinicians. J Psychiatr Res 12:189-198
13. Graber S, Hertrich I, Daum I, Spieker S, Ackermann H (2002) Speech perception deficits in Parkinson's disease: underestimation of time intervals compromises identification of durational phonetic contrasts. Brain Lang 82:65-74
14. Gross C, Rougier A, Guehl D, Boraud T, Julien J, Bioulac B (1997) High-frequency stimulation of the globus pallidus internalis in Parkinson's disease: a study of seven cases. J Neurosurg 87:491-498
15. Ho A, Bradshaw J, Iansek R, Alfredson R (1999) Speech volume regulation in Parkinson's disease: effects of implicit cues and explicit instructions. Neuropsychologia 37:1453-1460
16. Kataoka R, Warren DW, Zajac DJ, Mayo R, Lutz RW (2001) The relationship between spectral characteristics and perceived hypernasality in children. J Acoust Soc Am 109:2181-2189
17. Kent RD, Kent JF, Weismer G, Duffy JR (2000) What dysarthrias can tell us about the neural control of speech. J Phonetics 28:273-302
18. Klos KJ, Ahlskog JE, Josephs KA, Fealey RD, Cowl CT, Kumar N (2005) Neurologic spectrum of chronic liver failure and basal ganglia T1 hyperintensity on magnetic resonance imaging: probable manganese neurotoxicity. Arch Neurol 62:1385-1390
19. Levin OS (2005) "Ephedron" encephalopathy. Zh Nevrol Psikhiatr Im S S Korsakova 105:12-20 (in Russian)
20. McNeil MR (1997) Clinical management of sensomotoric speech disorders. Thieme, New York
21. Mousseau DD, Perney P, Layrargues GP, Butterworth RF (1993) Selective loss of pallidal dopamine D2 receptor density in hepatic encephalopathy. Neurosci Lett 162:192-196
22. Payan CA, Viallet F, Landwehrmeyer BG, Bonnet AM, Borg M, Durif F et al (2011) Disease severity and progression in progressive supranuclear palsy and multiple system atrophy: validation of the NNIPPS-Parkinson plus scale. PLoS One 6:e22293
23. Perl DP, Olanow CW (2007) The neuropathology of manganese-induced parkinsonism. J Neuropath Exp Neurol 66:675-682
24. Rusz J, Cmejla R, Ruzickova H, Ruzicka E (2011) Quantitative acoustic assessment of speech and voice disorders in early untreated Parkinson's disease. J Acoust Soc Am 129:350-367
25. Rusz J, Klempir J, Baborova E, Tykalova T, Majerova V, Cmejla R et al (2013a) Objective acoustic quantification of phonatory dysfunction in Huntington's disease. PLoS One 8:e65881
26. Rusz J, Cmejla R, Ruzickova H, Klempir J, Majerova V, Picmausova J et al (2013b) Evaluation of speech impairment in early stages of Parkinson's disease: a prospective study with the role of pharmacotherapy. J Neural Transm 120:319-329
27. Sanotsky Y, Lesyk R, Fedoryshyn L, Komnatska I, Matviyenko Y, Fahn S (2007) Manganic encephalopathy due to "ephedrone" abuse. Mov Disord 22:1337-1343
28. Sapir S, Spielman JL, Ramig LO, Story BH, Fox C (2007) Effects of intensive voice treatment (the Lee Silverman voice treatment [LSVT]) on vowel articulation in dysarthric individuals with idiopathic Parkinson disease: acoustic and perceptual findings. J Speech Lang Hear Res 50:899-912
29. Selikhova M, Fedoryshyn L, Matviyenko Y, Komnatska I, Kyrylchuk M, Krolicki L et al (2008) Parkinsonism and dystonia caused by the illicit use of ephedrone - a longitudinal study. Mov Disord 23:2224-2231
30. Sikk K, Haldre S, Aquilonius SM, Taba P (2011) Manganese-induced parkinsonism due to ephedrone abuse. Parkinsons Dis 865319. http://www.ncbi.nlm. nih.gov/pubmed/21403909
31. Skodda S, Flasskamp A, Schlegel U (2010) Instability of syllable repetition as a model for impaired motor processing: is Parkinson's disease a "rhythm disorder"? J Neural Transm 117:605-612
32. Stepens A, Logina I, Liguts V, Aldins P, Eksteina I, Platkajis A et al (2008) A parkinsonian syndrome in methcathinone users and the role of manganese. N Engl J Med 358:1009-1017
33. Zhingel KY, Dovensky W, Crossman A, Allen A (1991) Ephedrone: 2-methylamino-1-phenylpropan-1-one (Jeff). J Forensic Sci 36:915-920